论文部分内容阅读
由中国解放军总医院研制的血管栓塞剂丁氰酯(IBCA)及其治疗脑动静脉畸形(AVM)的临床应用研究最近在北京正式通过了鉴定。IBCA是目前国际上公认的最佳血管栓塞剂,具有粘度低,聚合迅速,可以在人体内永久存留等特点。颅内AVM患者以出血、癫痫和肢体瘫痪为主要临床表现,以往多采用手术切除的方法连行治疗,但对畸形部位深,病变范围大的病人手术难度很大,死亡率高。解放军总医院采用动脉导管术将直径仅0.7mm的显微导管送至病变部位进行超选择性血管造影并应用IBCA
The clinical application of embolic cyanogen embolide (IBCA) and its treatment of cerebral arteriovenous malformations (AVM) developed by Chinese PLA General Hospital recently passed the appraisal in Beijing. IBCA is internationally recognized as the best vascular embolization agent, with low viscosity, rapid polymerization, can persist in the human body and other characteristics. Intracranial AVM patients with bleeding, epilepsy and limb paralysis as the main clinical manifestations, the past, the use of surgical resection method of continuous treatment, but the deformity of deep, large lesions in patients with great difficulty in surgery, high mortality. People’s Liberation Army General Hospital, the use of catheterization of the diameter of only 0.7mm micro-catheter sent to the lesion for ultra-selective angiography and the application of IBCA